Potomac Law Advises Innovus Pharmaceuticals in Merger with Aytu BioScience

Potomac Law (“PLG”) is serving as special M&A counsel to Innovus Pharmaceuticals, Inc. (OTCQB: INNV) in its merger with a wholly-owned subsidiary of Aytu BioScience, Inc. (NASDAQ: AYTU).  The transaction was announced September 12, 2019 and is expected to close as early as December 2019, subject to customary closing conditions and regulatory approvals.  Under the terms of the merger agreement, Aytu will issue to Innovus shareholders a combination of stock and contingent value rights (CVRs), subject to the achievement of certain revenue and profitability milestones, for up to $24 million.

Innovus Pharmaceuticals is an emerging over the counter consumer goods and specialty pharmaceutical company commercializing, licensing and developing safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality.

Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address significant patient needs.

The PLG deal team was led by Laurent Campo (corporate) and included Rich McHugh (employee benefits) and James Warren (tax).